Clare R. Goyder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Clare R. Goyder has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Frederick David Richard Hobbs
University of Oxford
8 shared publications - Clare J. Taylor
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
6 shared publications - Nicholas Robert Jones
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
6 shared publications - Kathryn S. Taylor
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
4 shared publications - Helen Atherton
Primary Care Research Centre, University of Southampton, Southampton, UK
3 shared publications - Joseph Jonathan Lee
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
3 shared publications
Latest Publications
- 29 October 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (772) , 485-487
NICE chronic heart failure guideline update: implications for primary care
- 29 October 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (772) , 485-487
NICE chronic heart failure guideline update: implications for primary care
- Open Access
- 30 April 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (766) , 229-232
Missing by omission: the hidden heart of cardiovascular inequity in the UK
- 30 April 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (766) , 229-232
Open AccessMissing by omission: the hidden heart of cardiovascular inequity in the UK
- Open Access
- 30 March 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (768) , e534-e543
Conceptualising diagnostic liminality: a qualitative exploration of the journey to heart failure diagnosis
Background: Heart failure (HF) is a global public health priority. HF diagnosis in primary care is linked to improved outcomes, but most patients are diagnosed in hospital. The pathway to HF diagnosis in primary care is poorly understood. Aim: To gain deeper understanding of the patient experience of missed opportunities for HF diagnosis and develop recommendations for clinical practice. Design and setting: A qualitative study with patients recruited through general practice and community nurse clinics in England. Method: We conducted remote, semi-structured interviews with 24 patients who had a diagnosis of HF. Data were analysed using reflexive thematic analysis. Results: Three themes were developed: diagnostic liminality and suffering at the threshold of HF diagnosis (when participants were unwell but not yet diagnosed or were unaware of their diagnosis); meaning and framing in the diagnostic moment; and truth-telling and sense-making facilitating the escape from liminality. Although receiving the diagnosis brought relief, it also came as a shock owing to the meanings associated with the term. Some thought HF meant imminent death and was incompatible with living. Participants also described not being properly informed about their diagnosis. Conclusion: Although life was disrupted by an HF diagnosis, the diagnosis did not enable the transition from liminality. It was truth-telling, in combination with careful explanation, that facilitated the shift from diagnostic liminality. Through sense-making, participants were able to build an understanding of what an HF diagnosis actually meant for them and their future. Clinicians have a vitally important role in guiding patients away from diagnostic liminality through prompt HF diagnosis and thoughtful communication.
- 30 March 2026
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (768) , e534-e543
Open AccessConceptualising diagnostic liminality: a qualitative exploration of the journey to heart failure diagnosis
Background: Heart failure (HF) is a global public health priority. HF diagnosis in primary care is linked to improved outcomes, but most patients are diagnosed in hospital. The pathway to HF diagnosis in primary care is poorly understood. Aim: To gain deeper understanding of the patient experience of missed opportunities for HF diagnosis and develop recommendations for clinical practice. Design and setting: A qualitative study with patients recruited through general practice and community nurse clinics in England. Method: We conducted remote, semi-structured interviews with 24 patients who had a diagnosis of HF. Data were analysed using reflexive thematic analysis. Results: Three themes were developed: diagnostic liminality and suffering at the threshold of HF diagnosis (when participants were unwell but not yet diagnosed or were unaware of their diagnosis); meaning and framing in the diagnostic moment; and truth-telling and sense-making facilitating the escape from liminality. Although receiving the diagnosis brought relief, it also came as a shock owing to the meanings associated with the term. Some thought HF meant imminent death and was incompatible with living. Participants also described not being properly informed about their diagnosis. Conclusion: Although life was disrupted by an HF diagnosis, the diagnosis did not enable the transition from liminality. It was truth-telling, in combination with careful explanation, that facilitated the shift from diagnostic liminality. Through sense-making, participants were able to build an understanding of what an HF diagnosis actually meant for them and their future. Clinicians have a vitally important role in guiding patients away from diagnostic liminality through prompt HF diagnosis and thoughtful communication.
- Open Access
Body mass index and survival in people with heart failure
Aims In people with heart failure (HF), a high body mass index (BMI) has been linked with better outcomes (‘obesity paradox’), but there is limited evidence in community populations across long-term follow-up. We aimed to examine the association between BMI and long-term survival in patients with HF in a large primary care cohort. Methods We included patients with incident HF aged ≥45 years from the Clinical Practice Research Datalink (2000–2017). We used Kaplan-Meier curves, Cox regression and penalised spline methods to assess the association of pre-diagnostic BMI, based on WHO classification, with all-cause mortality. Results There were 47 531 participants with HF (median age 78.0 years (IQR 70–84), 45.8% female, 79.0% white ethnicity, median BMI 27.1 (IQR 23.9–31.0)) and 25 013 (52.6%) died during follow-up. Compared with healthy weight, people with overweight (HR 0.78, 95% CI 0.75 to 0.81, risk difference (RD) −4.1%), obesity class I (HR 0.76, 95% CI 0.73 to 0.80, RD −4.5%) and class II (HR 0.76, 95% CI 0.71 to 0.81, RD −4.5%) were at decreased risk of death, whereas people with underweight were at increased risk (HR 1.59, 95% CI 1.45 to 1.75, RD 11.2%). In those underweight, this risk was greater among men than women (p value for interaction=0.02). Class III obesity was associated with increased risk of all-cause mortality compared with overweight (HR 1.23, 95% CI 1.17 to 1.29). Conclusion The U-shaped relationship between BMI and long-term all-cause mortality suggests a personalised approach to identifying optimal weight may be needed for patients with HF in primary care. Underweight people have the poorest prognosis and should be recognised as high-risk.
Open AccessBody mass index and survival in people with heart failure
Aims In people with heart failure (HF), a high body mass index (BMI) has been linked with better outcomes (‘obesity paradox’), but there is limited evidence in community populations across long-term follow-up. We aimed to examine the association between BMI and long-term survival in patients with HF in a large primary care cohort. Methods We included patients with incident HF aged ≥45 years from the Clinical Practice Research Datalink (2000–2017). We used Kaplan-Meier curves, Cox regression and penalised spline methods to assess the association of pre-diagnostic BMI, based on WHO classification, with all-cause mortality. Results There were 47 531 participants with HF (median age 78.0 years (IQR 70–84), 45.8% female, 79.0% white ethnicity, median BMI 27.1 (IQR 23.9–31.0)) and 25 013 (52.6%) died during follow-up. Compared with healthy weight, people with overweight (HR 0.78, 95% CI 0.75 to 0.81, risk difference (RD) −4.1%), obesity class I (HR 0.76, 95% CI 0.73 to 0.80, RD −4.5%) and class II (HR 0.76, 95% CI 0.71 to 0.81, RD −4.5%) were at decreased risk of death, whereas people with underweight were at increased risk (HR 1.59, 95% CI 1.45 to 1.75, RD 11.2%). In those underweight, this risk was greater among men than women (p value for interaction=0.02). Class III obesity was associated with increased risk of all-cause mortality compared with overweight (HR 1.23, 95% CI 1.17 to 1.29). Conclusion The U-shaped relationship between BMI and long-term all-cause mortality suggests a personalised approach to identifying optimal weight may be needed for patients with HF in primary care. Underweight people have the poorest prognosis and should be recognised as high-risk.
- Open Access
- 13 February 2023
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (3) , 1643-1655
Diagnostic Accuracy of Natriuretic Peptide Screening for Left Ventricular Systolic Dysfunction in the Community: Systematic Review and Meta-Analysis
Aims: Heart failure (HF) is a global health burden and new strategies to achieve timely diagnosis and early intervention are urgently needed. Natriuretic peptide (NP) testing can be used to screen for left ventricular systolic dysfunction (LVSD), but evidence on test performance is mixed, and international HF guidelines differ in their recommendations. Our aim was to summarize the evidence on diagnostic accuracy of NP screening for LVSD in general and high-risk community populations and estimate optimal screening thresholds. Methods: We searched relevant databases up to August 2020 for studies with a screened community population of over 100 adults reporting NP performance to diagnose LVSD. Study inclusion, quality assessment, and data extraction were conducted independently and in duplicate. Diagnostic test meta-analysis used hierarchical summary receiver operating characteristic curves to obtain estimates of pooled accuracy to detect LVSD, with optimal thresholds obtained to maximize the sum of sensitivity and specificity. Results: Twenty-four studies were identified, involving 26 565 participants: eight studies in high-risk populations (at least one cardiovascular risk factor), 12 studies in general populations, and four in both high-risk and general populations combined. For detecting LVSD in screened high-risk populations with N-terminal prohormone brain natriuretic peptide (NT-proBNP), the pooled sensitivity was 0.87 [95% confidence interval (CI) 0.73–0.94] and specificity 0.84 (95% CI 0.55–0.96); for BNP, sensitivity was 0.75 (95% CI 0.65–0.83) and specificity 0.78 (95% CI 0.72–0.84). Heterogeneity between studies was high with variations in positivity threshold. Due to a paucity of high-risk studies that assessed NP performance at multiple thresholds, it was not possible to calculate optimal thresholds for LVSD screening in high-risk populations alone. To provide an indication of where the positivity threshold might lie, the pooled accuracy for LVSD screening in high-risk and general community populations were combined and gave an optimal cut-off of 311 pg/mL [sensitivity 0.74 (95% CI 0.53–0.88), specificity 0.85 (95% CI 0.68–0.93)] for NT-proBNP and 49 pg/mL [sensitivity 0.68 (95% CI 0.45–0.85), specificity 0.81 (0.67–0.90)] for BNP. Conclusions: Our findings suggest that in high-risk community populations NP screening may accurately detect LVSD, potentially providing an important opportunity for diagnosis and early intervention. Our study highlights an urgent need for further prospective studies, as well as an individual participant data meta-analysis, to more precisely evaluate diagnostic accuracy and identify optimal screening thresholds in specifically defined community-based populations to inform future guideline recommendations.
- 13 February 2023
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (3) , 1643-1655
Open AccessDiagnostic Accuracy of Natriuretic Peptide Screening for Left Ventricular Systolic Dysfunction in the Community: Systematic Review and Meta-Analysis
Aims: Heart failure (HF) is a global health burden and new strategies to achieve timely diagnosis and early intervention are urgently needed. Natriuretic peptide (NP) testing can be used to screen for left ventricular systolic dysfunction (LVSD), but evidence on test performance is mixed, and international HF guidelines differ in their recommendations. Our aim was to summarize the evidence on diagnostic accuracy of NP screening for LVSD in general and high-risk community populations and estimate optimal screening thresholds. Methods: We searched relevant databases up to August 2020 for studies with a screened community population of over 100 adults reporting NP performance to diagnose LVSD. Study inclusion, quality assessment, and data extraction were conducted independently and in duplicate. Diagnostic test meta-analysis used hierarchical summary receiver operating characteristic curves to obtain estimates of pooled accuracy to detect LVSD, with optimal thresholds obtained to maximize the sum of sensitivity and specificity. Results: Twenty-four studies were identified, involving 26 565 participants: eight studies in high-risk populations (at least one cardiovascular risk factor), 12 studies in general populations, and four in both high-risk and general populations combined. For detecting LVSD in screened high-risk populations with N-terminal prohormone brain natriuretic peptide (NT-proBNP), the pooled sensitivity was 0.87 [95% confidence interval (CI) 0.73–0.94] and specificity 0.84 (95% CI 0.55–0.96); for BNP, sensitivity was 0.75 (95% CI 0.65–0.83) and specificity 0.78 (95% CI 0.72–0.84). Heterogeneity between studies was high with variations in positivity threshold. Due to a paucity of high-risk studies that assessed NP performance at multiple thresholds, it was not possible to calculate optimal thresholds for LVSD screening in high-risk populations alone. To provide an indication of where the positivity threshold might lie, the pooled accuracy for LVSD screening in high-risk and general community populations were combined and gave an optimal cut-off of 311 pg/mL [sensitivity 0.74 (95% CI 0.53–0.88), specificity 0.85 (95% CI 0.68–0.93)] for NT-proBNP and 49 pg/mL [sensitivity 0.68 (95% CI 0.45–0.85), specificity 0.81 (0.67–0.90)] for BNP. Conclusions: Our findings suggest that in high-risk community populations NP screening may accurately detect LVSD, potentially providing an important opportunity for diagnosis and early intervention. Our study highlights an urgent need for further prospective studies, as well as an individual participant data meta-analysis, to more precisely evaluate diagnostic accuracy and identify optimal screening thresholds in specifically defined community-based populations to inform future guideline recommendations.
- Open Access
- 1 November 2022
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (726) , e1-e8
Natriuretic peptide testing and heart failure diagnosis in primary care: diagnostic accuracy study
Background: Natriuretic peptide (NP) testing is recommended for patients presenting to primary care with symptoms of chronic heart failure (HF) to prioritise referral for diagnosis.Aim: To report NP test performance at European Society of Cardiology (ESC) and National Institute for Health and Care Excellence (NICE) guideline referral thresholds.Design and setting: Diagnostic accuracy study using linked primary and secondary care data (2004 to 2018).Method: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of NP testing for HF diagnosis was assessed.Results: In total, 229 580 patients had an NP test and 21 102 (9.2%) were diagnosed with HF within 6 months. The ESC NT-proBNP threshold ≥125 pg/mL had a sensitivity of 94.6% (95% confidence interval [CI] = 94.2 to 95.0) and specificity of 50.0% (95% CI = 49.7 to 50.3), compared with sensitivity of 81.7% (95% CI = 81.0 to 82.3) and specificity of 80.3% (95% CI = 80.0 to 80.5) for the NICE NT-proBNP ≥400 pg/mL threshold. PPVs for an NT-proBNP test were 16.4% (95% CI = 16.1 to 16.6) and 30.0% (95% CI = 29.6 to 30.5) for ESC and NICE thresholds, respectively. For both guidelines, nearly all patients with an NT-proBNP level below the threshold did not have HF (NPV: ESC 98.9%, 95% CI = 98.8 to 99.0 and NICE 97.7%, 95% CI = 97.6 to 97.8).Conclusion: At the higher NICE chronic HF guideline NP thresholds, one in five cases are initially missed in primary care but the lower ESC thresholds require more diagnostic assessments. NP is a reliable ‘rule-out’ test at both cut-points. The optimal NP threshold will depend on the priorities and capacity of the healthcare system.
- 1 November 2022
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 73 (726) , e1-e8
Open AccessNatriuretic peptide testing and heart failure diagnosis in primary care: diagnostic accuracy study
Background: Natriuretic peptide (NP) testing is recommended for patients presenting to primary care with symptoms of chronic heart failure (HF) to prioritise referral for diagnosis.Aim: To report NP test performance at European Society of Cardiology (ESC) and National Institute for Health and Care Excellence (NICE) guideline referral thresholds.Design and setting: Diagnostic accuracy study using linked primary and secondary care data (2004 to 2018).Method: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of NP testing for HF diagnosis was assessed.Results: In total, 229 580 patients had an NP test and 21 102 (9.2%) were diagnosed with HF within 6 months. The ESC NT-proBNP threshold ≥125 pg/mL had a sensitivity of 94.6% (95% confidence interval [CI] = 94.2 to 95.0) and specificity of 50.0% (95% CI = 49.7 to 50.3), compared with sensitivity of 81.7% (95% CI = 81.0 to 82.3) and specificity of 80.3% (95% CI = 80.0 to 80.5) for the NICE NT-proBNP ≥400 pg/mL threshold. PPVs for an NT-proBNP test were 16.4% (95% CI = 16.1 to 16.6) and 30.0% (95% CI = 29.6 to 30.5) for ESC and NICE thresholds, respectively. For both guidelines, nearly all patients with an NT-proBNP level below the threshold did not have HF (NPV: ESC 98.9%, 95% CI = 98.8 to 99.0 and NICE 97.7%, 95% CI = 97.6 to 97.8).Conclusion: At the higher NICE chronic HF guideline NP thresholds, one in five cases are initially missed in primary care but the lower ESC thresholds require more diagnostic assessments. NP is a reliable ‘rule-out’ test at both cut-points. The optimal NP threshold will depend on the priorities and capacity of the healthcare system.
- Open Access
- 9 March 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (6) , 1489
Erratum. Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews. Diabetes Care 2021;44:2790–2811
Jamie Hartmann-Boyce, Karen Rees, James C. Perring, Sven A. Kerneis, Elizabeth M. Morris, Clare Goyder, Afolarin A. Otunla, Olivia E. James, Nandana R. Syam, Sa
- 9 March 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (6) , 1489
Open AccessErratum. Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews. Diabetes Care 2021;44:2790–2811
Jamie Hartmann-Boyce, Karen Rees, James C. Perring, Sven A. Kerneis, Elizabeth M. Morris, Clare Goyder, Afolarin A. Otunla, Olivia E. James, Nandana R. Syam, Sa
- Open Access
- 30 November 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (9) , 881-891
Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study
Heart failure (HF) is a malignant condition with poor outcomes and is often diagnosed on emergency hospital admission. Natriuretic peptide (NP) testing in primary care is recommended in international guidelines to facilitate timely diagnosis. We aimed to report contemporary trends in NP testing and subsequent HF diagnosis rates over time. Cohort study using linked primary and secondary care data of adult (≥45 years) patients in England 2004–18 (n = 7 212 013, 48% male) to report trends in NP testing (over time, by age, sex, ethnicity, and socioeconomic status) and HF diagnosis rates. NP test rates increased from 0.25 per 1000 person-years [95% confidence interval (CI) 0.23–0.26] in 2004 to 16.88 per 1000 person-years (95% CI 16.73–17.03) in 2018, with a significant upward trend in 2010 following publication of national HF guidance. Women and different ethnic groups had similar test rates, and there was more NP testing in older and more socially deprived groups as expected. The HF detection rate was constant over the study period (around 10%) and the proportion of patients without NP testing prior to diagnosis remained high [99.6% (n = 13 484) in 2004 vs. 76.7% (n = 12 978) in 2017]. NP testing in primary care has increased over time, with no evidence of significant inequalities, but most patients with HF still do not have an NP test recorded prior to diagnosis. More NP testing in primary care may be needed to prevent hospitalization and facilitate HF diagnosis at an earlier, more treatable stage. BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide.
- 30 November 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (9) , 881-891
Open AccessLong term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study
Heart failure (HF) is a malignant condition with poor outcomes and is often diagnosed on emergency hospital admission. Natriuretic peptide (NP) testing in primary care is recommended in international guidelines to facilitate timely diagnosis. We aimed to report contemporary trends in NP testing and subsequent HF diagnosis rates over time. Cohort study using linked primary and secondary care data of adult (≥45 years) patients in England 2004–18 (n = 7 212 013, 48% male) to report trends in NP testing (over time, by age, sex, ethnicity, and socioeconomic status) and HF diagnosis rates. NP test rates increased from 0.25 per 1000 person-years [95% confidence interval (CI) 0.23–0.26] in 2004 to 16.88 per 1000 person-years (95% CI 16.73–17.03) in 2018, with a significant upward trend in 2010 following publication of national HF guidance. Women and different ethnic groups had similar test rates, and there was more NP testing in older and more socially deprived groups as expected. The HF detection rate was constant over the study period (around 10%) and the proportion of patients without NP testing prior to diagnosis remained high [99.6% (n = 13 484) in 2004 vs. 76.7% (n = 12 978) in 2017]. NP testing in primary care has increased over time, with no evidence of significant inequalities, but most patients with HF still do not have an NP test recorded prior to diagnosis. More NP testing in primary care may be needed to prevent hospitalization and facilitate HF diagnosis at an earlier, more treatable stage. BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide.
- Open Access
Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004–2018
Objective Heart failure (HF) is a malignant condition requiring urgent treatment. Guidelines recommend natriuretic peptide (NP) testing in primary care to prioritise referral for specialist diagnostic assessment. We aimed to assess association of baseline NP with hospitalisation and mortality in people with newly diagnosed HF. Methods Population-based cohort study of 40 007 patients in the Clinical Practice Research Datalink in England with a new HF diagnosis (48% men, mean age 78.5 years). We used linked primary and secondary care data between 1 January 2004 and 31 December 2018 to report one-year hospitalisation and 1-year, 5-year and 10-year mortality by NP level. Results 22 085 (55%) participants were hospitalised in the year following diagnosis. Adjusted odds of HF-related hospitalisation in those with a high NP (NT-proBNP >2000 pg/mL) were twofold greater (OR 2.26 95% CI 1.98 to 2.59) than a moderate NP (NT-proBNP 400–2000 pg/mL). All-cause mortality rates in the high NP group were 27%, 62% and 82% at 1, 5 and 10 years, compared with 19%, 50% and 77%, respectively, in the moderate NP group and, in a competing risks model, risk of HF-related death was 50% higher at each timepoint. Median time between NP test and HF diagnosis was 101 days (IQR 19–581). Conclusions High baseline NP is associated with increased HF-related hospitalisation and poor survival. While healthcare systems remain under pressure from the impact of COVID-19, research to test novel strategies to prevent hospitalisation and improve outcomes—such as a mandatory two-week HF diagnosis pathway—is urgently needed.
Open AccessNatriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004–2018
Objective Heart failure (HF) is a malignant condition requiring urgent treatment. Guidelines recommend natriuretic peptide (NP) testing in primary care to prioritise referral for specialist diagnostic assessment. We aimed to assess association of baseline NP with hospitalisation and mortality in people with newly diagnosed HF. Methods Population-based cohort study of 40 007 patients in the Clinical Practice Research Datalink in England with a new HF diagnosis (48% men, mean age 78.5 years). We used linked primary and secondary care data between 1 January 2004 and 31 December 2018 to report one-year hospitalisation and 1-year, 5-year and 10-year mortality by NP level. Results 22 085 (55%) participants were hospitalised in the year following diagnosis. Adjusted odds of HF-related hospitalisation in those with a high NP (NT-proBNP >2000 pg/mL) were twofold greater (OR 2.26 95% CI 1.98 to 2.59) than a moderate NP (NT-proBNP 400–2000 pg/mL). All-cause mortality rates in the high NP group were 27%, 62% and 82% at 1, 5 and 10 years, compared with 19%, 50% and 77%, respectively, in the moderate NP group and, in a competing risks model, risk of HF-related death was 50% higher at each timepoint. Median time between NP test and HF diagnosis was 101 days (IQR 19–581). Conclusions High baseline NP is associated with increased HF-related hospitalisation and poor survival. While healthcare systems remain under pressure from the impact of COVID-19, research to test novel strategies to prevent hospitalisation and improve outcomes—such as a mandatory two-week HF diagnosis pathway—is urgently needed.
- Open Access
- 9 November 2020
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 22 (11) , e18218
Email Consultations Between Patients and Doctors in Primary Care: Content Analysis
Background: Increasingly, consultations in health care settings are conducted remotely using a range of communication technologies. Email allows for 2-way text-based communication, occurring asynchronously. Studies have explored the content and nature of email consultations to understand the use, structure, and function of email consultations. Most previous content analyses of email consultations in primary care settings have been conducted in North America, and these have shown that concerns and assumptions about how email consultations work have not been realized. There has not been a UK-based content analysis of email consultations. Objective: This study aims to explore and delineate the content of consultations conducted via email in English general practice by conducting a content analysis of email consultations between general practitioners (GPs) and patients. Methods: We conducted a content analysis of anonymized email consultations between GPs and patients in 2 general practices in the United Kingdom. We examined the descriptive elements of the correspondence to ascertain when the emails were sent, the number of emails in an email consultation, and the nature of the content. We used a normative approach to analyze the content of the email consultations to explore the use and function of email consultation. Results: We obtained 100 email consultations from 85 patients, which totaled 262 individual emails. Most email users were older than 40 years, and over half of the users were male. The email consultations were mostly short and completed in a few days. Emails were mostly sent and received during the day. The emails were mostly clinical in content rather than administrative and covered a wide range of clinical presentations. There were 3 key themes to the use and function of the email consultations: the role of the GP and email consultation, the transactional nature of an email consultation, and the operationalization of an email consultation. Conclusions: Most cases where emails are used to have a consultation with a patient in general practice have a shorter consultation, are clinical in nature, and are resolved quickly. GPs approach email consultations using key elements similar to that of the face-to-face consultation; however, using email consultations has the potential to alter the role of the GP, leading them to engage in more administrative tasks than usual. Email consultations were not a replacement for face-to-face consultations.
- 9 November 2020
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 22 (11) , e18218
Open AccessEmail Consultations Between Patients and Doctors in Primary Care: Content Analysis
Background: Increasingly, consultations in health care settings are conducted remotely using a range of communication technologies. Email allows for 2-way text-based communication, occurring asynchronously. Studies have explored the content and nature of email consultations to understand the use, structure, and function of email consultations. Most previous content analyses of email consultations in primary care settings have been conducted in North America, and these have shown that concerns and assumptions about how email consultations work have not been realized. There has not been a UK-based content analysis of email consultations. Objective: This study aims to explore and delineate the content of consultations conducted via email in English general practice by conducting a content analysis of email consultations between general practitioners (GPs) and patients. Methods: We conducted a content analysis of anonymized email consultations between GPs and patients in 2 general practices in the United Kingdom. We examined the descriptive elements of the correspondence to ascertain when the emails were sent, the number of emails in an email consultation, and the nature of the content. We used a normative approach to analyze the content of the email consultations to explore the use and function of email consultation. Results: We obtained 100 email consultations from 85 patients, which totaled 262 individual emails. Most email users were older than 40 years, and over half of the users were male. The email consultations were mostly short and completed in a few days. Emails were mostly sent and received during the day. The emails were mostly clinical in content rather than administrative and covered a wide range of clinical presentations. There were 3 key themes to the use and function of the email consultations: the role of the GP and email consultation, the transactional nature of an email consultation, and the operationalization of an email consultation. Conclusions: Most cases where emails are used to have a consultation with a patient in general practice have a shorter consultation, are clinical in nature, and are resolved quickly. GPs approach email consultations using key elements similar to that of the face-to-face consultation; however, using email consultations has the potential to alter the role of the GP, leading them to engage in more administrative tasks than usual. Email consultations were not a replacement for face-to-face consultations.